KLRK1 and glioblastoma: Combining NKG2D CAR-T cells with therapeutic agents that can upregulate NKG2D ligand expression in glioblastoma cells may overcome tumor antigen heterogeneity, immune escape problems, and significantly improve the efficacy of NKG2DL-directed immunotherapy.